Tempo Pharmaceuticals, a Cambridge, Mass., developer of new-drug formulations, raised $12.1 million in a first funding round. The company, which touts itself as a “nanopharmaceutical” maker, aims to improve the safety and effectiveness of existing drugs using engineered nanoparticles designed to home in on particular organs or tissues, then release two or more drugs in sequence. Tempo initially plans to focus on cancer.
Venrock and Polaris Venture Partners led the round, joined by Lux Capital and William Rastetter, former chairman of Biogen Idec. The company’s release is here; VentureWire has more here (subscription required).
11:37 am
VentureBeat » Life sciences briefing: Thursday, Oct. 11, 2007 said:
[...] we’ve written about include Tempo Pharmaceuticals and Carigent Therapeutics (see our coverage here and [...]
6:49 pm
VentureBeat » Life sciences briefing: Thursday, Dec. 3, 2008 said:
[...] second in just seven months; last May, it raised $12.1 million in a first round. (See our coverage here.) Tempo says the round reflects a “significantly increased [...]
1:24 pm
VentureBeat » Life sciences briefing: Thursday, Jan. 3, 2008 said:
[...] second in just seven months; last May, it raised $12.1 million in a first round. (See our coverage here.) Tempo says the round reflects a “significantly increased [...]